Dianthus Therapeutics (DNTH) Return on Capital Employed (2018 - 2025)

Dianthus Therapeutics' Return on Capital Employed history runs 8 years deep, the most recent figure standing at 32.79% for Q3 2025.

• On a quarterly basis, Return on Capital Employed fell 882.0% year-over-year to 32.79% in Q3 2025; TTM through Sep 2025 was 32.79%, a 882.0% decrease from a year earlier, with the FY2024 full-year figure at 39.44%, up 16.0% from the prior year.
• Return on Capital Employed improved to 32.79% in Q3 2025 per DNTH's latest filing, from 40.95% in the prior quarter.
• Across five years, Return on Capital Employed topped out at 18.8% in Q2 2024 and bottomed at 57.85% in Q1 2023.
• The 5-year median for Return on Capital Employed is 39.89% (2021), against an average of 38.67%.
• Across the five-year window, Return on Capital Employed jumped 3640 bps in 2024 and plunged 2215 bps in 2025, its largest moves.
• Year by year, Return on Capital Employed stood at 39.89% in 2021, then sank by 32 bps to 52.75% in 2022, then soared by 48 bps to 27.32% in 2023, then dropped by 8 bps to 29.47% in 2024, then retreated by 11 bps to 32.79% in 2025.
• Per Business Quant, the three latest DNTH Return on Capital Employed figures stand at 32.79% (Q3 2025), 40.95% (Q2 2025), and 34.04% (Q1 2025).